Orient Bio

Orient Bio Cash Flow per Share

The Operating Cash Flow per Share of Orient Bio (002630.KS) as of Oct 21, 2026 is 21.90 KRW. In the previous year, Operating Cash Flow per Share was 6.34 KRW — a change of 245.13% (higher).

Cash Flow per Share

21.90KRW

YoY

245.13%

Last updated:

Operating Cash Flow per Share of Orient Bio is 2026 21.90 KRW. Operating Cash Flow per Share of Orient Bio was 2025 6.34 KRW. It decreases by 245.13% higher compared to the previous year.

The Orient Bio Cash Flow per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Cash Flow per Share
Date
Cash Flow per Share
Jan 1, 2019
-113.36 KRW
Jan 1, 2020
-32.93 KRW
Jan 1, 2021
73.71 KRW
Jan 1, 2022
19.83 KRW
Jan 1, 2023
9.78 KRW
Jan 1, 2024
31.68 KRW
Jan 1, 2025
6.34 KRW
Jan 1, 2026
21.90 KRW
The Orient Bio Cash Flow per Share history
YEARCash Flow per ShareYoY
21.90KRW+245.13%
6.34KRW-79.97%
31.68KRW+223.86%
9.78KRW-50.67%
19.83KRW-73.10%
73.71KRW-323.82%
-32.93KRW-70.95%
-113.36KRW+466.68%
-20.00KRW-70.49%
-67.78KRW-649.39%
12.34KRW-8.74%
13.52KRW-26.10%
18.29KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Orient Bio Stock analysis

What does Orient Bio do? Orient Bio Inc generates revenue through the production and supply of laboratory animals such as mice, rats, guinea pigs, hamsters, SPF rabbits, and beagles. The company also offers CRO services including safety assessments and new drug development, alongside medical and library equipment like barrier systems. Additional income comes from support services such as rodent surgery, laboratory diagnostics, transgenic services, and genetic testing. The firm further provides feeds, reagents, disinfectants, automobile components, power supply equipment, and other machines through its subsidiaries. Orient Bio Inc's primary customers include research institutions, pharmaceutical companies, and medical facilities requiring laboratory animals and specialized services. The company's product segments consist of live animals, CRO services, medical equipment, and ancillary products like feeds and reagents. Subsidiaries contribute to revenue by supplying complementary items such as disinfectants and power supply equipment. The business model leverages a diversified portfolio of biotechnology products and services, targeting both direct research and development needs and ancillary support requirements. Revenue streams are derived from the sale of animals, provision of CRO services, equipment sales, and subsidiary product lines, ensuring steady income across multiple segments. Orient Bio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Orient Bio stock

Operating Cash Flow per Share of Orient Bio is 21.90 KRW in 2026.

Operating Cash Flow per Share of Orient Bio changed from 6.34 KRW to 21.90 KRW, representing a 245.13% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow per Share Orient Bio since 2006 – with annual values, charts, and detailed analysis.

Operating cash flow per share measures the operating cash generated per outstanding share.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Orient Bio

All Key Metrics — Orient Bio